Back to Search Start Over

Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.

Authors :
Fernandez‐Mercado, Marta
Pellagatti, Andrea
Di Genua, Cristina
Larrayoz, Maria Jose
Winkelmann, Nils
Aranaz, Paula
Burns, Adam
Schuh, Anna
Calasanz, Maria Jose
Cross, Nicholas C. P.
Boultwood, Jacqueline
Source :
British Journal of Haematology; Oct2013, Vol. 163 Issue 2, p235-239, 5p, 2 Charts
Publication Year :
2013

Abstract

Whole exome sequencing was performed in a patient with myelodysplastic syndrome before and after progression to acute myeloid leukaemia. Mutations in several genes, including SETBP1, were identified following leukaemic transformation. Screening of 328 patients with myeloid disorders revealed SETBP1 mutations in 14 patients (4·3%), 7 of whom had −7/del(7q) and 3 had i(17)(q10), cytogenetic markers associated with shortened overall survival and increased risk of leukaemic evolution. SETBP1 mutations were frequently acquired at the time of leukaemic evolution, coinciding with increase of leukaemic blasts. These data suggest that SETBP1 mutations may play a role in MDS and chronic myelomonocytic leukaemia disease progression. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00071048
Volume :
163
Issue :
2
Database :
Complementary Index
Journal :
British Journal of Haematology
Publication Type :
Academic Journal
Accession number :
90562354
Full Text :
https://doi.org/10.1111/bjh.12491